Celera Genomics Reports Second Quarter Fiscal 2006 Results (Hep C Treatment)

Celera Genomics Reports Second Quarter Fiscal 2006 Results
[Press Release] Business Wire via Yahoo! Finance - Jan 25 4:00 AM
ROCKVILLE, Md.----Jan. 25, 2006--Celera Genomics Group , an Applera Corporation business, today reported a net loss of $17.3 million, or $0.23 per share, for the second quarter of fiscal 2006 ended December 31, 2005, compared to a net loss of $19.4 million, or $0.27 per share, for the second quarter of fiscal 2005.Save to My Web

Schering-Plough to evaluate Peg-Intron in combined disease
Pharmaceutical Business Review - Jan 16 6:28 PM
Schering-Plough is set to initiate a large multinational clinical trial to evaluate the use of low-dose Peg-Intron maintenance monotherapy in patients who are infected with both hepatitis C and HIV.Save to My Web

Migenix: infectious ambitions in hepatitis
Pharmaceutical Business Review - Jan 25 5:56 PM
Migenix has confirmed plans to initiate a viral kinetics study with celgosivir in hepatitis C.Save to My Web

Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2005 Earnings Conference Call
[Press Release] PR Newswire via Yahoo! Finance - Jan 12 6:03 PM
Gen-Probe Incorporated announced today that the Company will release its fourth quarter and full year 2005 financial results on Wednesday, February 15, 2006 at approximately 4:00 p.m.Save to My Web